340 results about "Treated patient" patented technology

The invention relates to the field of medical equipment, and provides a compact multi-chamber proton treatment system based on a shared beam line, and the system comprises a fixed beam transmission line which is used for guiding the movement direction of a proton beam into a vertical direction; the rotating beam transmission line is used for guiding the movement direction of the proton beam into the horizontal direction; one end of the fixed beam transmission line is connected with the proton cyclotron, the other end of the fixed beam transmission line is connected with one end of the rotary beam transmission line, and the other end of the rotary beam transmission line is in butt joint with a plurality of treatment rooms; the rotating beam transmission line rotates around a central axis extending in the vertical direction. According to the invention, the proton beam can be safely, efficiently and accurately transmitted to each treatment room, and a fixed beam transmission system and a rotating rack do not need to be independently arranged for each treatment room, so that the beam control assembly and the system occupied area of the multi-room particle treatment device are minimized, and the number of treated patients can be remarkably increased.

Introduced here are pressure-mitigation systems able to mitigate the pressure applied to a human body by the surface of an object (also referred to as a "structure") and assist a caretaker to move the human body. A controller device (or simply "controller") can be fluidically coupled to a pressure-mitigation device that includes a series of selectively inflatable chambers. When a pressure-mitigation device is placed between a human body and a surface, the controller can continuously, intelligently, and autonomously circulate fluid through the chambers of the pressure-mitigation device. Normally, the controller circulates air through the chambers of the pressure-mitigation device, though the controller could circulate another fluid, such as water or gel, through the chambers of the pressure-mitigation device. The controller may cause the chambers to be selectively inflated, deflated, or any combination thereof. As chambers selectively inflate, certain portions of the human body may be lifted above the surface, turned, or any combination thereof.

In various embodiments, provided herein are methods, devices and systems for transcatheter mitral valve replacement in a double-orifice mitral valve. These methods, devices and systems are used to treat patients with mitral valve disease, particularly those who have had failed edge-to-edge leaflet repair, or patients presently considered anatomically unsuitable for edge-to-edge leaflet repair alone.

The invention provides an artery plaque intracavitary directional rotary cutting device and a using method thereof, and belongs to the technical field of medical instruments. The arterial plaque intracavitary directional rotary cutting device comprises a tool bit protection sleeve, a medicine storage part, a windmill type rotary cutting tool bit, a hollow spiral-line-shaped long-strip net bag structure recycling net, a metal supporting net, a guide pipe and a control unit. On the basis of having the advantages of a plaque excision device in the prior art, the artery plaque intracavity directional rotary cutting device further has the following advantages that (1) the rotary cutting position is accurate; (2) the medicine is suitable for treating patients with femoral popliteal lesion and below-knee arteriosclerosis obliterans; (3) the operation cost and the operation risk are low; (4) the stimulation and trauma to a patient are small in an operation; (5) the rotary cutting depth is long; (6) the cut plaques and chippings can be prevented from falling off; (7) the restenosis progress of blood vessels can be delayed, and inflammatory response and immune response caused by operations can be relieved; and (8) the device is easy to clean after operation.

The disclosure relates to methods of assessing the success of treatment with durvalumab and chemotherapy for resectable non-small cell lung cancer (R-NSCLC) in patients based on circulating tumor DNA (ctDNA) detection, ctDNA clearance and / or partial clearance and / or variant allele fraction (VAF) before and after such treatment. The disclosure also relates to methods for treating patients with R-NSCLC based on ctDNA detection, ctDNA clearance and / or partial molecular clearance and / or VAF before and after such treatment.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

Nicotine delivery devices and systems, particularly smoking cessation systems are provided by the present disclosure. Such devices and systems produce a nicotine-containing aerosol for inhalation that mimics smoking. The devices are capable of being adapted to control the amount of nicotine delivered to taper the amount of nicotine delivered to the user over time. Methods for treating patients to stop smoking are also disclosed. The devices, systems and methods can also be used to deliver other drugs disclosed herein, such as opioids (e.g., fentanyl).

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

Disclosed is a crystalline form of sepiapterin, a method of preparing the crystalline form, pharmaceutical compositions containing the crystalline form, and a method for treating patients with a disease associated with low intracellular BH4 levels or with dysfunction of various BH4 dependent metabolic pathways, which involves administering to the patient an effective amount of the crystalline form.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The present invention addresses the problem of providing a novel therapeutic agent for treating patients with anti NMDAR encephalitis. Patients with an anti NMDAR encephalitis have a pathogenic anti-human NR1 antibody that induces internalization of NMDAR on cell surface. As a result, NMDAR function is weakened in the patients' brain. The present inventors found that the one-armed anti-human NR1 antibody according to the present invention binds to NR1 competitively with the pathogenic anti-human NR1 antibody and inhibits the internalization of NMDAR by the pathogenic anti-human NR1 antibody to thereby exhibit therapeutic effect on anti NMDAR encephalitis. Accordingly, the present invention provides a one-armed anti-human NR1 antibody, a polynucleotide encoding the antibody, an expression vector containing the polynucleotide, a host cell transformed by the expression vector, a method for producing the antibody, a pharmaceutical composition comprising the antibody, a use of the antibody in the manufacture of the pharmaceutical composition, and a method for treating anti NMDAR encephalitis using the antibody.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The augmented-reality automated allergy office method comprises initially delivering a trace amount of a first allergen to a first test site via a multiple test applicator as the multiple test applicator delivers a trace amount of a second allergen to a second test site during allergen deposition. The multiple test applicator is cooperatively engageable with a fluid tray during allergen loading and with the patient's skin during allergen deposition. Then, capturing a first image of the first and second test site using a smart phone or tablet computer. Subsequently, capturing a second image of the first and second test site within 15 to 20 minutes after allergen deposition. And finally, developing a computer-generated treatment plan using machine learning for the patient with an allergy condition that is a step-by-step procedure, the computer-generated treatment plan being stored in a medical database for treating patients with the allergy condition.

The present invention provides compounds of the formula:wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cancer.

The invention is a method for treating patients with Parkinson's disease, primary parkinsonism / idiopathic parkinsonism, post-encephalitic parkinsonism, parkinsonism that may follow carbon monoxide intoxication, or parkinsonism that may follow manganese intoxication and provides an improvement of a patient's total post-dose “On” time or “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The present invention is in the field of ocular disease therapy. In particular, the invention relates to a composition comprising pimecrolimus for use in the topical treatment of moderate to severe blepharitis, in particular in a patient group comprising subjects with a clinical diagnosis of moderate to severe blepharitis, wherein the subjects to be treated have signs and symptoms of moderate to severe blepharitis characterised by swelling of the eyelid margin, ocular debris and ocular discomfort. In particular, the present invention relates to an ophthalmic composition that shows a high patient acceptance and a clinically meaningful improvement in the signs and symptoms of treated patients.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition with the effects of treating atrial fibrillation and improving anxiety, a medicine and a preparation method and application thereof. When the traditional Chinese medicine composition provided by the invention is combined with auricular point pressing beans to treat patients with atrial fibrillation and anxiety, clinical symptoms of atrial fibrillation and anxiety can be further improved, specifically, the score of traditional Chinese medicine syndromes is reduced, the effective rate of electrocardiograms and the clinical effective rate of anxiety are improved, the life quality of the patients is improved, and no obvious adverse reaction exists. Meanwhile, a traditional Chinese medicine oral administration and traditional Chinese medicine external treatment combined method is adopted, syndrome differentiation treatment can be carried out from the holism concept, the holographic therapy of external treatment of internal diseases can be utilized to the maximum extent, and a simple, convenient, safe and effective treatment thought is provided for early prevention, early diagnosis and early treatment of more diseases.

Provided herein are methods for determining a subtype of a small cell lung cancer in a patient based on the express status of ASCL1, NEUROD1, and POU2F3, which are expressed in a mutually exclusive fashion. The subtype of the cancer can be used to determine the sensitivity of the cancer to certain anti-cancer therapies. As such, also provided are methods of treating patients having small cell lung cancer based on the subtyping results.

The present invention relates to a topical formulation comprising at least one anticholinergic compound for use in treating patients suffering from severe hyperhidrosis, wherein administration of the formulation to the patient comprises: a) an initial phase with a topical administration of a predetermined amount of the formulation 5 to 7 times per week for a total time period of less than six months: followed by b) a maintenance phase with a topical administration of the same amount of the formulation 1 to less than 5 times per week.

Disclosed herein is a method of treating patients with NSCLC subtypes of cancer by reducing tumor burden, comprising administering at least one dose of purified Ruthenium (III) Pyrazole complexes to patients suffering from NSCLC, wherein said dose is therapeutically sufficient. In one or more embodiments, the Ruthenium III Pyrazole is RuCl3(DMSO)(dmPyz)2.

1. Name of the designed product: Non-invasive respirator (HepoRes R2). 2. Use of the designed product: Medical equipment for treating patients with respiratory insufficiency requiring mechanical ventilation. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: perspective view 1.

To provide a method of treating a patient with chronic heart failure using a medicament comprising neuregulin.SOLUTION: A companion diagnostic test is first performed on each patient prior to treatment, and the appropriate treatment is provided to each patient according to the companion diagnostic test results. If the test results are within a preferred therapeutic range for treatment, the patient is suitable for treatment of heart failure by administration of an effective amount of neuregulin.SELECTED DRAWING: None

The present disclosure provides liposomal particles comprising one or more active pharmaceutical ingredients (APIs) comprising at least one poorly water-soluble API located in an aqueous phase compartment inside the particle, pharmaceutical compositions thereof, and methods of preparing the same, and methods of preparing the same. And the use of the drug-loaded liposome and the pharmaceutical composition thereof for treating patients (including various types of cancer patients) to achieve a synergistic treatment effect. Also disclosed are therapeutic kits, dosage forms, and methods of preparing the drug-loaded liposomes and pharmaceutical compositions thereof.

The present disclosure provides methods for treating patients with myasthenia gravis, particularly patients who have been diagnosed of myasthenia gravis within 2 years.

The present invention relates to pharmaceutical compositions and methods for obtaining said pharmaceutical compositions comprising a conditioned culture medium of human mesenchymal stem cells and / or a combination of trophic factors expressed by human mesenchymal stem cells, and a polymeric matrix of hyaluronic acid. The present invention also relates to methods for preventing and / or treating patients having pathologies that generate tortuous vessels, or complications from the appearance of tortuous vessels, such as varicose veins, psoriasis, hemorrhoids, rosacea, acne, crystal skin, atopic dermatitis, among others.

The present invention provides tissue processing systems, apparatus, and methods. [Solution] Provided herein is a system for treating patient tissue. The system comprises an energy delivery console and at least one energy delivery device. The energy delivery console can deliver a first dose of energy and a second dose of energy. The energy delivery device comprises a first delivery element configured to deliver a first dose of energy to target tissue and a second delivery element configured to deliver a second dose of energy to target tissue. The first dose of energy may include the delivery of energy that reversibly alters the target tissue, and the second dose of energy may include the delivery of energy that irreversibly alters the target tissue. The first dose of energy is delivered to enhance the therapy provided by the second dose of energy.

The present invention relates inter alia to a combination of (i) a BCL-2 inhibitor and (ii) SEL24 / MEN1703 for use as a medicine, preferably for use in treating patients suffering from cancer. The present invention also relates to a kit of dosage forms comprising (i) a dosage form comprising a BCL-2 inhibitor and (ii) a dosage form comprising SEL24 / MEN1703, and to dosage forms comprising (i) a BCL-2 inhibitor and (ii) SEL24 / MEN1703.